World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
65
Citations
18406
World Ranking
9031
National Ranking
4016

Overview

Charles Flexner is affiliated with Johns Hopkins University in the United States and specializes primarily in the field of medicine. Their research focuses extensively on infectious diseases, with a significant portion dedicated to HIV/AIDS drug development and treatment.

The main fields of study for Charles Flexner include:

  • Medicine

Their subfields of study consist of:

  • Infectious Diseases
  • Virology
  • Epidemiology
  • Molecular Biology
  • Hepatology

The core topics covered in their research encompass:

  • HIV/AIDS drug development and treatment
  • HIV Research and Treatment
  • HIV/AIDS Research and Interventions
  • Hepatitis C virus research
  • Pneumocystis jirovecii pneumonia detection and treatment
  • HIV, Drug Use, Sexual Risk
  • HIV-related health complications and treatments

Charles Flexner has published papers in several frequent venues, including:

  • Clinical Infectious Diseases
  • The Lancet HIV
  • Pharmaceutics
  • Clinical Pharmacology & Therapeutics
  • Current Opinion in HIV and AIDS

Some of the recent papers involving Charles Flexner or related coauthors include:

  • "Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications," 2022, Clinical Pharmacology & Therapeutics
  • "Long-acting drugs and formulations for the treatment and prevention of HIV infection," 2020, International Journal of Antimicrobial Agents
  • "The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis," 2021, The Lancet Global Health
  • "Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study," 2023, The Lancet HIV
  • "Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV," 2024, JAMA Cardiology

Frequent collaborators include:

  • Andrew Owen
  • Marco Siccardi
  • Andrew Phillips
  • Loveleen Bansi-Matharu
  • Paul Revill

Best Publications

  • Latent infection of CD4 + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

    Diana Finzi;Joel N Blankson;Janet M Siliciano;Joseph Bernard Margolick

  • HIV-Protease Inhibitors

    Charles Flexner

  • Pharmacokinetics and Safety of AMD-3100, a Novel Antagonist of the CXCR-4 Chemokine Receptor, in Human Volunteers

    Craig W. Hendrix;Charles Flexner;Ronald T. MacFarland;Christen Giandomenico

  • The effect of systemically administered recombinant human nerve growth factor in healthy human subjects

    Brent G. Petty;David R. Cornblath;Bruce T. Adornato;Vinay Chaudhry

  • Intermittent HIV-1 Viremia (Blips) and Drug Resistance in Patients Receiving HAART

    Richard E. Nettles;Tara L. Kieffer;Tara L. Kieffer;Patty Kwon;Daphne Monie

  • Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection

    Craig W. Hendrix;Ann C. Collier;Michael Marcel Lederman;Dominique Schols

  • Vaccinia Virus Expression Vectors

    Bernard Moss;Charles Flexner

  • HIV drug development: the next 25 years

    Charles Flexner

  • Sporadic Urban Leptospirosis

    Joseph M. Vinetz;Gregory E. Glass;Charles E. Flexner;Paul Mueller

  • Chemotherapy for Human Immunodeficiency Virus–Associated Non-Hodgkin’s Lymphoma in Combination With Highly Active Antiretroviral Therapy

    Lee Ratner;Jeannette Lee;Shenghui Tang;David Redden

  • Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.

    Roy M. Gulick;Zhaohui Su;Charles Flexner;Michael D. Hughes

  • Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors.

    Paul Dowell;Charles Flexner;Peter O. Kwiterovich;M. Daniel Lane

  • Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: Prospective randomized comparison with parenteral therapy

    Alan W. Heldman;Tina V. Hartert;Stuart C. Ray;Emile G. Daoud

  • Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo.

    Athe M N Tsibris;Bette Tm Korber;Bette Tm Korber;Ramy Arnaout;Ramy Arnaout;Ramy Arnaout;Carsten Russ

  • HIV Type 1 Chemokine Coreceptor Use among Antiretroviral-Experienced Patients Screened for a Clinical Trial of a CCR5 Inhibitor: AIDS Clinical Trial Group A5211

    Timothy J. Wilkin;Zhaohui Su;Daniel R. Kuritzkes;Michael Hughes

  • Vancomycin-Resistant and Vancomycin-Susceptible Enterococcal Bacteremia: Comparison of Clinical Features and Outcomes

    Gregory M. Lucas;Noah Lechtzin;D. Wonder Puryear;Linda L. Yau

  • Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects.

    Kelly E. Dooley;Patrick Sayre;Julie Borland;Elizabeth Purdy

  • Drug Interactions in Patients Infected with Human Immunodeficiency Virus

    Stephen C. Piscitelli;Charles Flexner;James R. Minor;Michael A. Polis

  • Updated guideline to perform therapeutic drug monitoring for antiretroviral agents.

    C.J.L. la Porte;D. Back;T. Blaschke;C.A.B. Boucher

  • Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection.

    C Flexner;P A Barditch-Crovo;D M Kornhauser;H Farzadegan

Frequent Co-Authors

Roy M. Gulick
Roy M. Gulick Cornell University
Daniel R. Kuritzkes
Daniel R. Kuritzkes Brigham and Women's Hospital
Robert F. Siliciano
Robert F. Siliciano Johns Hopkins University School of Medicine
David Back
David Back University of Liverpool
Michael M. Lederman
Michael M. Lederman Case Western Reserve University
Robert E. Gross
Robert E. Gross Emory University
Thomas C. Quinn
Thomas C. Quinn Johns Hopkins University
Martin S. Hirsch
Martin S. Hirsch Harvard Medical School
Joseph J. Eron
Joseph J. Eron University of North Carolina at Chapel Hill
Bernard Moss
Bernard Moss National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

A degree in Biology or Biochemistry opens doors to diverse career pathways, and many students are now exploring flexible online options for advanced study. If you are interested in leadership roles in healthcare, consider a degree in healthcare management. With this qualification, you can transition into administrative or managerial positions within hospitals, clinics, or pharmaceutical companies.

For those wanting to specialize further, the shortest pmhnp program can speed up your journey to becoming a Psychiatric Mental Health Nurse Practitioner, integrating biology with mental healthcare.

Nutrition is another fast-growing field. Programs like the fastest nutrition degree online can help you quickly acquire the skills needed for roles in dietetics, wellness coaching, or research.

Advancement often means additional business skills. For cost-conscious students, the cheapest online mba healthcare management offers a budget-friendly way to gain a business edge and move into upper management in the healthcare sector.

Best Scientists Citing Charles Flexner

Trending Scientists

Recently Published Articles